Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: L01BC01

DepoCyte(cytarabine)

Meningeal Neoplasms

Marketing Authorisation Holder: Pacira Limited

EMA Authorisation: 11/07/2001

INN: cytarabine

Indication

Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about DepoCyte — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.